The patches which are marked as supplements, not medication purport to aid in weight management appetite control
As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)
Obesity and type 2 diabetes are recognized as comorbidities for low testosterone and sexual dysfunction
Attitudes also remained largely unchanged among adults 65 and older, among those who have taken GLP-1s and those who have not, and among independents and Republicans
Beneficiaries on the Bridge program would still be responsible for paying the $50 copay, even if they have met the $2,100 deductible for Part D, Tsai says
Several medications used for fibromyalgia symptoms can also contribute to weight gain